priority health glp-1 coverage GLP-1s and The Payer Predicament Coverage of Obesity Therapies in

Understanding the difference between expected slowing and pathological delay helps patients use semaglutide and tirzepatide safely

The primary drivers

Among the marketed large molecule injectable GLP-1 agonists, semaglutide, apart from weight-loss, is being studied for kidney disease and tirzepatide (a dual GLP-1 and GIP receptor agonist) is being evaluated for sleep apnea in Ph 3 clinical trials

This patient-crafted GLP1 Symptom Tracker will help you to gain insight about your daily habits and how they are affecting your overall GLP1 journey!Crafted by a GLP1 patient, it includes metrics you won't find in a typical symptom trackers such as injection day, bathroom habits (we all know this is important on a GLP1), injection location, weekly dosage, water instake, caloric and sleep goals met, and so much more

Track GLP-1 injections, weight, menstrual cycles, symptoms, and meals in one private journal